Cite
HARVARD Citation
Oza, A. et al. (n.d.). 2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC). European journal of cancer. pp. S532-. [Online].